3′,4′-dihydroxyflavonol reduces superoxide and improves nitric oxide function in diabetic rat mesenteric arteries

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Leo, Chen Huei ^a   Hart, Joanne L ^a   Woodman, Owen L ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3',4' DIHYDROXYFLAVONOL; ACETYLCHOLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; FLAVONOL DERIVATIVE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE; UNCLASSIFIED DRUG; 3',4'-DIHYDROXYFLAVONOL; CYBB PROTEIN, RAT; MEMBRANE PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SCAVENGER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DRUG SENSITIVITY; ENDOTHELIAL DYSFUNCTION; MALE; MESENTERIC ARTERY; NONHUMAN; PROTEIN EXPRESSION; RAT; VASODILATATION; ANIMAL; BLOOD; BODY WEIGHT; DRUG EFFECT; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MICROVASCULATURE; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; WISTAR RAT;

RATTUS;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; ENDOTHELIUM, VASCULAR; FLAVONOLS; FREE RADICAL SCAVENGERS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MALE; MEMBRANE GLYCOPROTEINS; MESENTERIC ARTERIES; MICROVESSELS; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, WISTAR; SUPEROXIDES; VASODILATION;

EID: 79958092697     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020813     Document Type: Article

References (51)

1. De Vriese AS, Verbeuren TJ, Van de Voorde J, Vanhoutte PM, (2000) Endothelial dysfunction in diabetes. Br J Pharmacol 130: 963-974.
2. Fatehi-Hassanabad Z, Chan CB, Furman BL, (2010) Reactive oxygen species and endothelial function in diabetes. Eur J Pharmacol 636: 8-17.
3. Holman RR, Paul SK, Bethel A, Matthews DR, Neil HAW, (2008) 10-year follow-up of intensive glucose control in tpe 2 diabetes. N Engl J Med 359: 1577-1589.
4. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653.
5. Brown A, Reynolds R, Bruemmer D, (2010) Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 7: 369-375.
6. Brownlee M, (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
7. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, et al. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790.
8. Forstermann U, (2008) Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 5: 338-349.
9. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, et al. (2002) Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and MICRO-HOPE substudy. Diabetes Care: 25: 1919-1927.
10. Song Y, Cook NR, Albert CM, Denburgh MV, Manson JE, (2009) Effects of vitamin C and E and β-carotene on the risk of type 2 diabetes in woman at high risk of cardiovascular disease: a randomized controlled trial. Am J Clin Nutr 90: 429-437.
11. Johansen J, Harris A, Rychly D, Ergul A, (2005) Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice. Cardiovasc Diabetology 4: 1-11.
12. Willcox BJ, Curb JD, Rodriguez BL, (2008) Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol 101: 75D-86D.
13. Hink U, Li H, Mollnau H, Oelze M, Matheis E, et al. (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: 14-22.
14. Woodman OL, Chan ECH, (2004) Vascular and anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol Physiol 31: 786-790.
15. Yap S, Qin CX, Woodman OL, (2010) Effects of resveratrol and flavonols on cardiovascular function: Physiological mechanisms. Biofactors 36: 350-359.
16. Engler MB, Engler MM, (2006) The emerging role of flavonoid-rich cocoa and chocolate in cardiovascular health and disease. Nutr Rev 64: 109-118.
17. Geleijnse JM, Launer LJ, Van der Kuip DA, Hofman A, Witteman JC, (2002) Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam Study. Am J Clin Nutr 75: 880-886.
18. Machha A, Achike FI, Mustafa AM, Mustafa RM, (2007) Quercetin, a flavonoid, modulates endothelium-derived nitric oxide bioavailability in diabetic rat aortas. Nitric Oxide 16: 441-447.
19. Coskun O, Kanter M, Korkmaz A, Oter S, (2005) Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol Res 51: 117-123.
20. Anjaneyulu M, Chopra K, (2004) Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 31: 244-248.
21. Woodman OL, Meeker WF, Boujaoude M, (2005) Vasorelaxant and antioxidant activity of flavonols and flavones: Structure-activity relationships. J Cardiovasc Pharmacol 46: 302-309.
22. Chan EC, Pannangpetch P, Woodman OL, (2000) Relaxation to flavones and flavonols in rat isolated thoracic aorta: mechanism of action and structure-activity relationships. J Cardiovasc Pharmacol 35: 326-333.
23. Chan EC, Drummond GR, Woodman OL, (2003) 3′, 4'-Dihydroxyflavonol enhances nitric oxide bioavailability and improves vascular function after ischemia and reperfusion injury in the rat. J Cardiovasc Pharmacol 42: 727-735.
24. Qin CX, Chen XQ, Hughes RA, Williams SJ, Woodman OL, (2008) Understanding the cardioprotective effects of flavonols: Discovery of relaxant flavonols without antioxidant activity. J Med Chem 51: 1847-1884.
25. Wang S, Dusting GJ, May CN, Woodman OL, (2004) 3',4'-Dihydroxyflavonol reduces infarct size and injury associated with myocardial ischaemia and reperfusion in sheep. Br J Pharmacol 142: 443-452.
26. Wang S, Thomas CJ, Dusting GJ, Woodman OL, May CN, (2009) 3′,4′-Dihydroxyflavonol improves post-ischaemic coronary endothelial function following 7 days reperfusion in sheep. Eur J Pharmacol 624: 31-37.
27. Woodman OL, Malakul W, (2009) 3′,4′-Dihydroxyflavonol prevents diabetes-induced endothelial dysfunction in rat aorta. Life Sci 85: 54-59.
28. Leo CH, Hart JL, Woodman OL, (2011) 3′,4′-dihydroxyflavonol restores endothelium dependent relaxation in small mesenteric artery from rats with type 1 and type 2 diabetes. Eur J Pharmacol In Press.
29. Mladenka P, Zatloukalova L, Filipsky T, Hrdina R, (2010) Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity. Free Rad Biol Med 49: 963-975.
30. Leo CH, Hart JL, Woodman OL, (2011) Impairment of both nitric oxide-mediated and EDHF-type relaxation in small mesenteric arteries from rats with streptozotocin-induced diabetes. Br J Pharmacol 162: 365-377.
31. Ding H, Hashem M, Wiehler WB, Lau W, Martin J, et al. (2005) Endothelial dysfunction in the streptozotocin-induced diabetic apoE-deficient mouse. Br J Pharmacol 146: 1110-1118.
32. Malakul W, Thirawarapan S, Suvitayavat W, Woodman OL, (2007) Type 1 diabetes and hypercholesterolaemia reveal the contribution of endothelium-derived hyperpolarizing factor to endothelium-dependent relaxation of the rat aorta. Clin Exp Pharmacol Physiol 35: 192-200.
33. Leo CH, Joshi A, Woodman OL, (2010) Short term type 1 diabetes alters the mechanism of endothelium-dependent relaxation in the rat carotid artery. Am J Physiol Heart Circ Physiol 299: H502-H511.
34. Jiang F, Guo N, Dusting GJ, (2008) Modulation of nicotinamide adenine dinucleotide phosphate oxidase expression and function by 3',4'-dihydroxyflavonol in phagocytic and vascular cells. J Pharmacol Exp Ther 324: 261-269.
35. Edwards G, Feletou M, Weston AH, (2010) Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch 459: 863-879.
36. Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabatake A, (1997) Alteration in endothelium-dependent hyperpolarization and relaxation in mesenteric arteries from streptozotocin-induced diabetic rats. Br J Pharmacol 121: 1383-1391.
37. Matsumoto T, Kobayashi T, Kamata K, (2003) Alteration in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats. Am J Physiol Heart Circ Physiol 285: H283-H291.
38. Matsumoto T, Kobayashi T, Wakabayashi K, Kamata K, (2005) Cilostazol improves endothelium-derived hyperpolarizing factor type relaxation in mesenteric arteries from diabetic rats. Am J Physiol Heart Circ Physiol 289: H1933-H1940.
39. Burnham MP, Johnson IT, Weston AH, (2006) Impaired small-conductance Ca2+-activated K+ channel-dependent EDHF responses in type II ZDF rats. Br J Pharmacol 148: 434-441.
40. Weston AH, Absi M, Harno E, Geraghty AR, Ward DT, et al. (2008) The expression and function of Ca2+-sensing receptors in rat mesenteric artery; comparative studies using a model of type II diabetes. Br J Pharmacol 154: 652-662.
41. Matsumoto T, Miyamori K, Kobayashi T, Kamata K, (2006) Specific impairment of endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from streptozotocin-induced diabetic mice. Vasc Pharmacol 44: 450-460.
42. Makino A, Ohuchi K, Kamata K, (2000) Mechanisms underlying the attenuation of endothelium-dependent vasodilatation in the mesenteric arterial bed of the streptozotocin-induced diabetic rat. Br J Pharmacol 130: 549-556.
43. Ma X, Li YF, Gao Q, Ye ZG, Lu XJ, et al. (2008) Inhibition of superoxide anion-mediated impairment of endothelium by treatment with luteolin and apigenin in rat mesenteric artery. Life Sci pp. 110-117.
44. Erlund I, Kosonen T, Alfthan G, Mäenpää J, Perttunen K, et al. (2000) Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56: 545-553.
45. Loke WM, Hodgson JM, Proudfoot JM, McKinley AJ, Puddey IB, et al. (2008) Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am J Clin Nutr 88: 1018-1025.
46. Qi W, Chen X, Holian J, Tan CY, Kelly DJ, et al. (2009) Transcription factors Krüppel-like factor 6 and peroxisome proliferator-activated receptor γ mediate high glucose-induced thioredoxin-interacting protein. Am J Pathol 175: 1858-1867.
47. McPherson GA, (1992) Assessing vascular reactivity of arteries in the small vessel myograph. Clin Exp Pharmacol Physiol 19: 815-825.
48. Mulvany MJ, Halpern W, (1977) Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41: 19-26.
49. Klatt P, Schmidt K, Lehner D, Glatter O, Bachinger HP, et al. (1995) Structural analysis of porcine brain nitric oxide synthase reveals a role for tetrahydrobiopterin and L-arginine in the formation of an SDS-resistant dimer. EMBO J 14: 3687-3695.
50. Heumüller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, et al. (2008) Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51: 211-217.
51. Shi Y, Vanhoutte PM, (2008) Oxidative stress and COX cause hyper-responsiveness in vascular smooth muscle of the femoral artery from diabetic rats. Br J Pharmacol 154: 639-651.